Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. Among authors: namikawa k. EClinicalMedicine. 2023 Oct 31;65:102290. doi: 10.1016/j.eclinm.2023.102290. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37965433 Free PMC article.
Metastatic melanoma on the abdominal wall.
Namikawa K, Yamazaki N. Namikawa K, et al. Jpn J Clin Oncol. 2009 May;39(5):336. doi: 10.1093/jjco/hyp042. Jpn J Clin Oncol. 2009. PMID: 19403735 No abstract available.
BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, Oashi K, Ogawa T, Hayashi A, Nakamura N, Tsuta K. Yamazaki N, et al. Among authors: namikawa k. Melanoma Res. 2015 Feb;25(1):9-14. doi: 10.1097/CMR.0000000000000091. Melanoma Res. 2015. PMID: 25051202 Free PMC article.
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N, Uhara H, Fukushima S, Uchi H, Shibagaki N, Kiyohara Y, Tsutsumida A, Namikawa K, Okuyama R, Otsuka Y, Tokudome T. Yamazaki N, et al. Among authors: namikawa k. Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25. Cancer Chemother Pharmacol. 2015. PMID: 26407818 Free PMC article. Clinical Trial.
284 results